The Conversation (0)
09 December
Invion Advances Global Strategy With New Licencing Agreement
Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
27 November
5 Biggest Pharmaceutical ETFs in 2025
The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
18 November
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
04 November
4 Best-performing Canadian Pharma Stocks of 2025
From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
30 October
New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says
Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00






